Latest Breaking News On - Riccardo lencioni - Page 2 : comparemela.com

Durvalumab and Bevacizumab Plus TACE Improves PFS in Embolization-Eligible, Unresectable HCC

PFS was significantly improved with durvalumab plus bevacizumab and TACE vs TACE alone in patients with unresectable HCC eligible for embolization.

Italy
Japan
Riccardo-lencioni
Department-of-surgery
Critical-area-pathology
Druvalumab-and-bevacizumab-plus-tace
Dotace
Hcc
Hepatocellular-carcinoma
Gastrointestinal-cancer
Gi-cancer
Asco-gi

EMERALD-1: Durvalumab and Bevacizumab Plus TACE Improves PFS in Patients With Unresectable HCC

One expert said the results have the potential to change the standard of care for some patients with the most common type of liver cancer.

Italy
California
United-states
San-francisco
Barcelona
Comunidad-autonoma-de-cataluna
Spain
American
Riccardo-lencioni
Cathy-eng
Division-of-hematology
Department-of-medicine

AstraZeneca shares positive phase 3 results for Imfinzi combination in liver cancer

AstraZeneca shares positive phase 3 results for Imfinzi combination in liver cancer
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Japan
Susan-galbraith
Riccardo-lencioni
Genentech-avastin
Astrazeneca

Durvalumab regimen extends PFS in certain patients with liver cancer

Durvalumab regimen extends PFS in certain patients with liver cancer
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Italy
Bymatthew-shinkle
Mindy-valcarcel
Riccardo-lencioni
Pisa-university-hospital
Genentech
Astrazeneca

Durvalumab Plus TACE and Bevacizumab Significantly Improves PFS in Select HCC

Durvalumab plus concurrent transarterial chemoembolization followed by durvalumab with bevacizumab resulted in a significant improvement in PFS over TACE alone in patients with hepatocellular carcinoma who are eligible for embolization, meeting the primary end point of the phase 3 EMERALD-1 trial.

Sangro
Italy-general
Italy
Riccardo-lencioni
Susan-galbraith
Durvalumab-imfinzi
International-liver-cancer-association-virtual-conference
Cancer-imaging-program
Astrazeneca
Interventional-radiology
Pisa-university-hospital
Liver-cancer-association-virtual-conference